Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (August 2021)
15 slides from Century Therapeutics's investor presentation, Aug 12, 2021
Slide 1: Corporate Overview August 2021
CORPORATE OVERVIEW August 2021
Slide 2: Forward-Looking Statements
2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical f
Slide 3: Century Therapeutics - Emerging Leader in iPSC Cell Therapies
3 3 CENTURY THERAPEUTICS - EMERGING LEADER IN i PSC CELL THERAPIES EMPLOYEES INCLUDING EXPERIENCED LEADERS AND ENTREPRENEURS ~120 COMPREHENSIVE iPSC CELL PLATFORM FOR IMMUNE EFFECTOR CELLS LEAD PROGRAM EXPECTED TO FILE IND IN MID 2022 STATE - OF - THE ART GMP MANUFACTURING FACILITY EXPECTED TO BE OP
Slide 4: Proven Leadership Team
4 4 Osvaldo (Lalo) Flores, CEO Hy Levitsky , President R&D Adrienne Farid, COO Greg Russotti , CTO Luis Borges, CSO Michael Diem, CBO PROVEN LEADERSHIP TEAM
Slide 5: iPSC Technology Can Overcome Limitations of Donor-Derived Platforms
5 5 Allogeneic, donor - derived Multiple donors Fewer doses per batch • Complex manufacturing, heterogeneous product, limited scale • Limited genetic engineering options Allogeneic, i PSC - derived Greater doses per batch • Efficient manufacturing, homogeneous product, greater scale • Likely unlimit
Slide 6: Foundational Investments in iPSC Know-How and Manufacturing
6 6 FOUNDATIONAL INVESTMENTS IN iPSC KNOW - HOW AND MANUFACTURING 6 In - House Manufacturing accelerates learnings and enables faster product iteration • Century facility expected to be operational by the end of 2021 • 53,000 ft 2 facility • Designed to produce multiple immune cell types • Two sites
Slide 7: Integrated Cell Engineering and Manufacturing Enables Rapid Product Iteration
7 7 Sequential gene edits Engineered iPSC iNK cell iT cell iPSC bank Cell Engineering Manufacturing INTEGRATED CELL ENGINEERING AND MANUFACTURING ENABLES RAPID PROD UCT ITERATION ITERATIVE ENHANCEMENT OF PRODUCT FITNESS AND FUNCTIONALITY Engineered iPSC MCB Differentiation
Slide 8: Allo-Evasion Technology
8 8 ALLO - EVASION TM TECHNOLOGY b 2M KO (HLA - I) HLA - E CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell NK cell Evading the dominant mediators of allo - rejection
Slide 9: Illustrative Potential of Allo-Evasion on Cellular Pharmacokinetics
9 9 Not for further distribution ILLUSTRATIVE POTENTIAL OF ALLO - EVASION TM ON CELLULAR PHARMACOKINETICS Repeat doses With Allo - Evasion TM engineering Without Allo - Evasion TM engineering Time Cell count Initial dose
Slide 10: Century's Approach to Optimizing Anti-Tumoral Response
10 10 CENTURY’S APPROACH TO OPTIMIZING ANTI - TUMORAL RESPONSE Potentially maximizing durability of clinical responses and efficacy Genetic Engineering (To improve fitness) Manufacturing Optimization (To improve product quality) Engineered CAR - iNK or CAR - iT cells Allo - Evasion TM To avoid rejec
Slide 11: iNK Cell Platform Is Our Most Advanced Platform
11 11 iNK CELL PLATFORM IS OUR MOST ADVANCED PLATFORM CNTY - 101, our first product candidate is a CAR - iNK cell engineered with multiple features Allo - Evasion Persistence Safety switch CD19 - CAR 0 5 10 15 20 0 2.0×10 8 4.0×10 8 6.0×10 8 8.0×10 8 1.0×10 9 1.2×10 9 Day Post-tumor Implantation A v
Slide 12: Our iT Cell Platform Is Closely Behind and Making Demonstrable Progress
12 12 OUR i T CELL PLATFORM IS CLOSELY BEHIND AND MAKING DEMONSTRABLE PROGRESS Developing ab and gd iT platforms with Trusted TCRs that are not expected to cause GvHD CAR TCR 0 5 10 15 20 0 5.0×10 8 1.0×10 9 1.5×10 9 2.0×10 9 2.5×10 9 Day Post-tumor Implantation A v e r a g e R a d i a n c e ( p / s
Slide 13: Pipeline
13 13 Product iPSC Platform Targets Indications Ownership Expected IND Submission Discovery Preclinical Phase 1 Phase 2 Phase 3 CNTY - 101 iNK CD19 Lymphoma Mid 2022 CNTY - 103 iNK CD133 + EGFR Glioblastoma 1H 2023 CNTY - 102 iT or iNK CD19 + CD79b Lymphoma 2H 2023 CNTY - 104 iT or iNK Multi - speci
Slide 14: Century's Next Generation iPSC Technology Platform
14 14 CENTURY’S NEXT GENERATION i PSC TECHNOLOGY PLATFORM Broad product pipeline with first 1 st IND submission targeting M id - 2022 Precision gene editing Advanced manufacturing Allo - Evasion Ρ Protein engineering iPSC - derived NK cells iPSC - derived T cells Comprehensive allogeneic iPSC - base
Slide 15: Century Therapeutics
CENTURY THERAPEUTICS.
Century Therapeutics — Investor Presentation (August 2021) on 6ix